<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00738348</url>
  </required_header>
  <id_info>
    <org_study_id>ESAR</org_study_id>
    <secondary_id>Kochi University</secondary_id>
    <nct_id>NCT00738348</nct_id>
  </id_info>
  <brief_title>Effect of Perioperative Sivelstat Administration for Liver Resection</brief_title>
  <acronym>KMS</acronym>
  <official_title>Effect of Perioperative Sivelstat Administration for Liver Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kochi University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kochi University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is reported that sivelstat improved and preserved the postoperative renal function in the
      orthopedic management. Moreover because sivelstat reduced the migration of neutrophil, it
      improved acute lung injury. During liver resection, Pringle maneuver, clamping the
      hepatoduodenal ligament, was performed. Pringle maneuver causes reperfusion injury of the
      liver. We have a hypothesis that sivelstat prevent the warm shock of reperfusion injury of
      the liver by Pringle maneuver.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Whether the incidence of postoperative morbidities, such as liver failure, renal failure, or
      congestive heart failure, was reduced by administration of perioperative sivelstat.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of liver damage due to reperfusion injury by Pringle maneuver was measured by several cytokines, including IL-8, IL-6, and HMGB-1.</measure>
    <time_frame>during hospitalization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The duration of ICU stay and hospital stay, postoperative complications, and the liver damage at 6 POD, measuring hepato-biliary enzyme</measure>
    <time_frame>during hospitalization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Liver Diseases</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>250mL of 5% glucose plus 300mg of sivelstat was infected through the vein at 10mL per an hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>250mL of 5% glucose was injected though the vein at 10mL per an hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sivelstat</intervention_name>
    <description>sivelstat sodiumhydrate</description>
    <arm_group_label>2</arm_group_label>
    <other_name>sivelstat sodiumhydrate, ONO PHARMACEUTICAL CO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glucose</intervention_name>
    <description>glucose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  liver disease which surgical management was indicated

        Exclusion Criteria:

          -  weight loss greater than 10 per cent during the previous 6 months, signs of distant
             metastasis, or of respiratory, renal or heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takehiro Okabayashi, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kochi Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kochi Medical School</name>
      <address>
        <city>Kohasu-Okocho, Nankoku</city>
        <zip>783-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2008</study_first_submitted>
  <study_first_submitted_qc>August 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2008</study_first_posted>
  <last_update_submitted>June 6, 2012</last_update_submitted>
  <last_update_submitted_qc>June 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kochi University</investigator_affiliation>
    <investigator_full_name>Takehiro Okabayashi</investigator_full_name>
    <investigator_title>University</investigator_title>
  </responsible_party>
  <keyword>surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

